Kinetic Spectrophotometric Determination of Gemifloxacin Mesylate and Moxifloxacin Hydrochloride in Pharmaceutical Preparations Using 4-Chloro-7-nitrobenzo-2-oxa-1,3-diazole

Table 8

Application of the proposed methods for the determination of GMF and MOX in their pharmaceutical preparations.

Sample	Proposed method	Reference methods^c
Factive tablets
X ± SD^a	99.95±0.69	100.08±0.56
𝑡-value^b	0.33
𝐹-value^b	1.52
Flobiotic tablets
X ± SD^a	100.05±0.74	99.94±0.68
𝑡-value^b	0.24
𝐹-value^b	1.18
GemiQue tablets
X ± SD^a	99.90±0.72	99.85±0.49
𝑡-value^b	0.13
𝐹-value^b	2.16
Avelox tablets
X ± SD^a	99.47±1.12	99.03±0.97
𝑡-value^b	0.66
𝐹-value^b	1.33
Moxiflox tablets
X ± SD^a	99.68±0.58	99.34±0.34
𝑡-value^b	1.13
𝐹-value^b	2.91
Moxifloxacin tablets
X ± SD^a	99.80±0.87	99.94±0.92
𝑡-value^b	0.25
𝐹-value^b	1.12

aMean for six independent analyses.
^bTheoretical values for 𝑡- and 𝐹-values at five degrees of freedom and 95% confidence limit are (𝑡=2.57) and (𝐹=5.05).
^cReference methods for GMF [26] and MOX [36].